Literature DB >> 26584779

Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus.

Jiaxin Hu1, Jing Liu1, Liande Li1, Keith T Gagnon2, David R Corey3.   

Abstract

A GGGGCC expansion within an intronic region of the C9orf72 gene forms RNA foci that are associated with one-third of familial amyotrophic lateral sclerosis and one-quarter of frontotemporal dementia. The C9orf72 locus also expresses an antisense transcript with a CCCCGG expansion that forms foci and may contribute to disease. Synthetic agents that bind these hexanucleotide repeats and block foci would be leads for therapeutic discovery. We have engineered duplex RNAs to enable them to recognize difficult C/G targets. Recognition inhibits foci formed by both GGGGCC and CCCCGG RNA. Our findings show that a single duplex RNA can be used to recognize both disease-related C9orf72 transcripts. More broadly, we extend RNAi to previously inaccessible C/G sequences and provide another example of target recognition in human cells by nuclear RNAi.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26584779      PMCID: PMC4659491          DOI: 10.1016/j.chembiol.2015.09.016

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  22 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 2.  Designing highly active siRNAs for therapeutic applications.

Authors:  S Patrick Walton; Ming Wu; Joseph A Gredell; Christina Chan
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

Review 3.  Allele-selective inhibition of trinucleotide repeat genes.

Authors:  Masayuki Matsui; David R Corey
Journal:  Drug Discov Today       Date:  2012-01-18       Impact factor: 7.851

Review 4.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

5.  Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

Authors:  Jiaxin Hu; Jing Liu; David R Corey
Journal:  Chem Biol       Date:  2010-11-24

6.  siRNA design principles and off-target effects.

Authors:  Sebastian Petri; Gunter Meister
Journal:  Methods Mol Biol       Date:  2013

7.  RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.

Authors:  Krzysztof Sobczak; Thurman M Wheeler; Wenli Wang; Charles A Thornton
Journal:  Mol Ther       Date:  2012-11-27       Impact factor: 11.454

8.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

9.  Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats.

Authors:  Agnieszka Fiszer; Agnieszka Mykowska; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2011-03-22       Impact factor: 16.971

10.  Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway.

Authors:  Jiaxin Hu; Jing Liu; Dongbo Yu; Yongjun Chu; David R Corey
Journal:  Nucleic Acids Res       Date:  2012-10-04       Impact factor: 16.971

View more
  9 in total

1.  Duplex RNAs and ss-siRNAs Block RNA Foci Associated with Fuchs' Endothelial Corneal Dystrophy.

Authors:  Jiaxin Hu; Xiulong Shen; Frank Rigo; Thahza P Prakash; V Vinod Mootha; David R Corey
Journal:  Nucleic Acid Ther       Date:  2019-01-24       Impact factor: 5.486

2.  Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs.

Authors:  Jiaxin Hu; Frank Rigo; Thazha P Prakash; David R Corey
Journal:  Nucleic Acid Ther       Date:  2016-12-22       Impact factor: 5.486

3.  c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA.

Authors:  Jing Liu; Jiaxin Hu; Andrew T Ludlow; Jacqueline T Pham; Jerry W Shay; Jeffrey D Rothstein; David R Corey
Journal:  Cell Chem Biol       Date:  2017-01-26       Impact factor: 8.116

Review 4.  Development of disease-modifying drugs for frontotemporal dementia spectrum disorders.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Davide Seripa; Antonio Daniele; Mark Watling; Gianluigi Giannelli
Journal:  Nat Rev Neurol       Date:  2020-03-23       Impact factor: 42.937

Review 5.  Gene therapy for ALS: A review.

Authors:  Defne A Amado; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

6.  Targeting RNA-Mediated Toxicity in C9orf72 ALS and/or FTD by RNAi-Based Gene Therapy.

Authors:  Raygene Martier; Jolanda M Liefhebber; Ana García-Osta; Jana Miniarikova; Mar Cuadrado-Tejedor; Maria Espelosin; Susana Ursua; Harald Petry; Sander J van Deventer; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther Nucleic Acids       Date:  2019-02-11

7.  Structural Diversity of Sense and Antisense RNA Hexanucleotide Repeats Associated with ALS and FTLD.

Authors:  Tim Božič; Matja Zalar; Boris Rogelj; Janez Plavec; Primož Šket
Journal:  Molecules       Date:  2020-01-25       Impact factor: 4.411

Review 8.  Gene Therapy in Amyotrophic Lateral Sclerosis.

Authors:  Ton Fang; Goun Je; Peter Pacut; Kiandokht Keyhanian; Jeff Gao; Mehdi Ghasemi
Journal:  Cells       Date:  2022-06-29       Impact factor: 7.666

9.  Analyzing pre-symptomatic tissue to gain insights into the molecular and mechanistic origins of late-onset degenerative trinucleotide repeat disease.

Authors:  Yongjun Chu; Jiaxin Hu; Hanquan Liang; Mohammed Kanchwala; Chao Xing; Walter Beebe; C Bradley Bowman; Xin Gong; David R Corey; V Vinod Mootha
Journal:  Nucleic Acids Res       Date:  2020-07-09       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.